A pair of directives issued in May and June 2026 has triggered a wave of internal restructuring, asset divestments, and suspended fundraising across China's state-owned private equity sector.
From $9/month · 7-day free trial
Already a subscriber? Log in
Ten government agencies jointly published China's pharmaceutical industry roadmap on September 21, 2026, setting a 20%+ annual growth target for innovative drugs and aiming for Chinese-developed first-in-class drugs to represent more than 25% of global new drug approvals by 2030.
China expanded its precursor chemical export licensing catalogue on 22 September 2026, adding two piperidine-derivative compounds with fentanyl precursor relevance.
Eight hours of pre-summit trade talks in New York produced an AI notification framework and operationalised a Board of Trade covering USD 30 billion in non-sensitive goods per side. A November 2026 truce expiry remains unresolved, with rare earth compliance flagged as a sticking point.
Subscribe for full access to all articles
Start Free Trial